• Explore /
  • Poster
  • / Phase I trial of lorlatinib in combination with topotecan/cyclophosphamide in children with ALK-driven refractory or relapsed neuroblastoma: A new approaches to neuroblastoma therapy consortium study.

Phase I trial of lorlatinib in combination with topotecan/cyclophosphamide in children with ALK-driven refractory or relapsed neuroblastoma: A new approaches to neuroblastoma therapy consortium study.

Abstract Poster

Authors

null

Kelly C. Goldsmith

Children's Healthcare of Atlanta, Emory University, Atlanta, GA

Kelly C. Goldsmith , Yael P. Mosse , Kimberly Kayser , Yueh-Yun Chi , Marc Chioda , Holger C. Thurm , Joseph Chen , Sriram Krishnaswami , Gerson Peltz , Meaghan Granger , Rajen Mody , Lynley V. Marshall , Ami Vijay Desai , Esther Berko , John M. Maris , Katherine K. Matthay , Suzy Ghazarian , Julie R. Park , Araz Marachelian

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2022 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Pediatric Oncology

Track

Pediatric Oncology

Sub Track

Pediatric Solid Tumors

Clinical Trial Registration Number

NCT03107988

Citation

J Clin Oncol 40, 2022 (suppl 16; abstr 10041)

DOI

10.1200/JCO.2022.40.16_suppl.10041

Abstract #

10041

Poster Bd #

256

Abstract Disclosures

Similar Posters

First Author: Araz Marachelian

First Author: Kim Schellekens

First Author: Jifang Gong

First Author: Steven G. DuBois